N-linked sulfonamides of N-heterocyclic carboxylic acids or carboxylic acid isosteres
AssigneeGuilford Pharmaceuticals Inc.
InventorsGregory S. Hamilton, Mark H. Norman, Yong-Qian Wu
Life of this patent
Estimating the term…
Abstract
This invention relates to novel N-linked sulfonamides of N-heterocyclic carboxylic acid and carboxylic acid isosteres, their preparation, and use for treating neurological disorders including physically damaged nerves and neurodegenerative diseases, and for treating alopecia and promoting hair growth.
Claims71
A compound having the formula (I):
- 30
- where
- n is 1-3;
- R1 is selected from the group consisting of hydrogen, C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, or heterocycle;
- D is a bond, or a C1-C10 straight or branched chain alkyl, C2-C10 alkenyl or C2-C10 alkynyl;
- R2is a carboxylic acid or a carboxylic acid isostere;
- wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle, or carboxylic acid isostere is optionally substituted with one or more substituents selected from R3, where
- R3 is hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C1-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl or alkynyl, aryl, heteroaryl, carbocycle, heterocycle, or CO2R4 where R4 is hydrogen or C1-C9 straight or branched chain alkyl or alkenyl;
- or a pharmaceutically acceptable salt, ester or solvate thereof;
- provided that:
- when D is a bond, and R2 is COOH, then R1 cannot be substituted naphthyl;
- further provided that:
- when D is a bond, and n is 1, and R2 is COOH or CONHR3, then R1 is not hydroxyl, methyl, ethyl, substituted or unsubstituted thioethyl, benzothiazole, substituted benzopyran, substituted benzopyrrole, substituted benzoxazole, substituted 5-membered heterocycle containing two N and one S heteroatoms, or substituted or unsubstituted phenyl, phenylethyl, naphthyl, pyridyl, thienyl, quinoline, tricyclic ring, aminoethyl, or benzyl;
- further provided that:
- when D is a bond, and n is 2, and R2 is COOH or phenylbutyl ester, then R1 is not substituted phenyl, or a substituted bicyclic ring containing two oxygen heteroatoms.
- further provided that:
- when D is a bond, and n is 1-2, and R2 is a substituted or unsubstituted carbocyclic or heterocyclic ring structure, then R1 is not substituted or unsubstituted carbocycle or heterocycle, or hydroxy;
- further provided that:
- when D is a bond, and n is 1-2, and R2 is hydroxy, alkoxy, —SO2(phenyl), N(R3)2, substituted thio or alkylthio, —NCO, —PO3(Me)2, or —NCOOC(ethyl)phenyl, then R1 is not naphthalene, ethylene, substituted tricyclic ring, or substituted or unsubstituted phenyl;
- further provided that:
- when D is C1-C3 alkyl or hexenyl, and R2 is hydroxyl,
- then R1 is not substituted or unsubstituted phenyl, or benzoimidazole;
- further provided that:
- when D is methyl, and n is 1, and R2 is cyano or COOH, then R1 is not substituted phenyl;
- further provided that:
- when D is methyl, and n is 1, and R2 is methoxy or N(R3)2, then R1 is not methyl, ethyl, phenylethyl, chloro substituted alkyl, substituted oxirane, substituted aziridine wherein one of the carbons is replaced with an oxygen, substituted or unsubstituted propenyl, substituted phenyl, benzyl, or trifluoro substituted C2-C3 alkyl or alkenyl;
- further provided that:
- when D is ethyl, and n is 2, and R2 is hydroxyl or N(R3)2, then R1 is not naphthyl;
- further provided that:
- when D is propyl, and n is 1, and R2 is methoxy, then R1 is not ethylene, cyano substituted ethyl, or triethoxy substituted propyl;
- further provided that:
- when D is not a bond and at least one of D and R2 contains at least one S or O, then R1 is not methyl or substituted phenyl.
The compounds, (2S)-1-(phenylmethyl)sulfonyl-2-hydroxymethyl pyrrolidine;
- ( 2S )-1-(phenylmethyl)sulfonyl-2-pyrrolidinetetrazole.
A pharmaceutical composition, comprising:
- a) an effective amount of an N-linked sulfonamide of an N-heterocyclic carboxylic acid or carboxylic acid isostere;
- and
- b) a pharmaceutically acceptable carrier.
A method of treating a neurological disorder in an animal, comprising:
- administering to the animal an effective amount of an N-linked sulfonamide of an N-heterocyclic carboxylic acid or carboxylic acid isostere to stimulate growth of damaged peripheral nerves or to promote neuronal regeneration.
A method of stimulating growth of damaged peripheral nerves, comprising:
- administering to damaged peripheral nerves a therapeutically effective amount of an N-linked sulfonamide of an N-heterocyclic carboxylic acid or carboxylic acid isostere to stimulate or promote growth of the damaged peripheral nerves.
A method for promoting neuronal regeneration and growth in animals, comprising:
- administering to an animal a therapeutically effective amount of a neurotrophic N-Linked sulfonamide of an N-heterocyclic carboxylic acid or carboxylic acid isostere to promote neuronal regeneration.
A method for preventing neurodegeneration in an animal, comprising:
- administering to an animal a therapeutically effective amount of a neurotrophic N-linked sulfonamide of an N-heterocyclic carboxylic acid or carboxylic acid isostere to prevent neurodegeneration.
A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of an N-linked sulfonamide of an N-heterocyclic carboxylic acid or carboxylic acid isostere.
A pharmaceutical composition comprising:
- (i) an effective amount of a N-linked sulfonamide of an N-heterocyclic carboxylic acid or carboxylic acid isostere for treating alopecia or promoting hair growth in an animal;
- and
- (ii) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.